PK150 (Sorafenib Analog)
Product Code: AG-CR1-0162
Product Group: Antibiotics and Other Antimicrobials
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CR1-0162-M001 | 1 mg | £30.00 |
Quantity:
| AG-CR1-0162-M005 | 5 mg | £45.00 |
Quantity:
| AG-CR1-0162-M025 | 25 mg | £120.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
Antibiotic PK150; 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)urea
Appearance:
White to off-white solid.
CAS:
2165324-62-7
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08
Handling Advice:
Keep cool and dry.
Hazards:
H302,H361,H373
InChi:
InChI=1S/C15H8ClF5N2O3/c16-10-3-1-7(5-9(10)14(17,18)19)22-13(24)23-8-2-4-11-12(6-8)26-15(20,21)25-11/h1-6H,(H2,22,23,24)
InChiKey:
SHPYXCLUNMOJOB-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 2165324-62-7. Formula: C15H8ClF5N2O3. MW: 394.7. Analog of the anticancer drug sorafenib. PK150 is a potent antibiotic. It shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively. PK150 did not induce in vitro resistance and shows oral bioavailability and in vivo efficacy. The mode of action includes the interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltransferase and the stimulation of protein secretion by altering the activity of signal peptidase IB.
MDL:
MFCD32667017
Molecular Formula:
C15H8ClF5N2O3
Molecular Weight:
394.7
Package Type:
Vial
Precautions:
P301+P312, P308+P313
Product Description:
Analog of the anticancer drug sorafenib. PK150 is a potent antibiotic. It shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively. PK150 did not induce in vitro resistance and shows oral bioavailability and in vivo efficacy. The mode of action includes the interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltransferase and the stimulation of protein secretion by altering the activity of signal peptidase IB.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
O=C(NC1=CC(OC(F)(F)O2)=C2C=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Solubility Chemicals:
Soluble in DMSO (25mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms: P. Le, et al.; Nat. Chem. 12, 145 (2020)